SELLAS Life Sciences Group, Inc.

DB:RXK3 Stock Report

Market Cap: €69.1m

SELLAS Life Sciences Group Management

Management criteria checks 3/4

SELLAS Life Sciences Group's CEO is Angelos Stergiou, appointed in Dec 2012, has a tenure of 11.92 years. total yearly compensation is $1.75M, comprised of 35.7% salary and 64.3% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth €61.23K. The average tenure of the management team and the board of directors is 4.8 years and 6.9 years respectively.

Key information

Angelos Stergiou

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage35.7%
CEO tenure11.9yrs
CEO ownership0.09%
Management average tenure4.8yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Angelos Stergiou's remuneration changed compared to SELLAS Life Sciences Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$34m

Mar 31 2024n/an/a

-US$36m

Dec 31 2023US$2mUS$625k

-US$37m

Sep 30 2023n/an/a

-US$38m

Jun 30 2023n/an/a

-US$36m

Mar 31 2023n/an/a

-US$36m

Dec 31 2022US$2mUS$594k

-US$41m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$2mUS$565k

-US$21m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$1mUS$541k

-US$17m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$1mUS$630k

-US$28m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019n/an/a

-US$32m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$1mUS$549k

-US$41m

Sep 30 2018n/an/a

-US$37m

Jun 30 2018n/an/a

-US$32m

Mar 31 2018n/an/a

-US$30m

Dec 31 2017US$729kUS$400k

-US$24m

Compensation vs Market: Angelos's total compensation ($USD1.75M) is above average for companies of similar size in the German market ($USD483.75K).

Compensation vs Earnings: Angelos's compensation has been consistent with company performance over the past year.


CEO

Angelos Stergiou (48 yo)

11.9yrs

Tenure

US$1,752,638

Compensation

Dr. Angelos M. Stergiou, MD, Sc.D. h.c., is the Founder, President, Chief Executive Officer and Director of SELLAS Life Sciences Group, Inc. (formerly known as SELLAS Life Sciences Group AG) (formerly, Sel...


Leadership Team

NamePositionTenureCompensationOwnership
Angelos Stergiou
Founder11.9yrsUS$1.75m0.089%
€ 61.2k
John Burns
Senior VP & CFO6.9yrsUS$797.71k0.040%
€ 27.8k
Stacy Yeung
VP, Associate General Counsel & Head of Complianceless than a yearno datano data
Dragan Cicic
Senior Vice President of Clinical Development4.8yrsUS$859.54k0.044%
€ 30.2k
Andrew Elnatan
VP and Head of Regulatory Affairs1.8yrsno datano data

4.8yrs

Average Tenure

48yo

Average Age

Experienced Management: RXK3's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Angelos Stergiou
Founder11.9yrsUS$1.75m0.089%
€ 61.2k
Robert Van Nostrand
Independent Director6.9yrsUS$106.28k0.0068%
€ 4.7k
John Varian
Independent Director6.9yrsUS$110.50k0.0068%
€ 4.7k
David Scheinberg
Independent Director6.9yrsUS$102.50k0.0071%
€ 4.9k
Jane Wasman
Independent Chairman6.9yrsUS$136.28k0.0068%
€ 4.7k
Jeffrey Weber
Chairman of Scientific Advisory Board8yrsno datano data
Sattva Neelapu
Member of Scientific Advisory Boardno datano datano data
Larry W. Kwak
Member of Scientific Advisory Board9yrsno datano data
Javier Pinilla-Ibarz
Member of Scientific Advisory Board8yrsno datano data
Guenther Koehne
Member of Scientific Advisory Boardno datano datano data
Katherine Kalin
Independent Director2.3yrsUS$92.50k0.0068%
€ 4.7k

6.9yrs

Average Tenure

65.5yo

Average Age

Experienced Board: RXK3's board of directors are considered experienced (6.9 years average tenure).